In the discovery study cohort, albumin was significantly increased and immunoglobulins (IgG, IgA, IgM) were slightly elevated in PCNSL tumor patients in contrast to tumor-free control patients and confirmed that in 58% of the analyzed PCNSL patients, the BBB is disrupted. The gene discussed is CD79A; the disease is primary central nervous system lymphoma.